Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients.
Nasopharyngeal non-Hodgkin lymphomas (NNHL) are extremely rare. In this study, we will report the progress achieved in the management of this disease in our institute.
Methods: We retrospectively reviewed the records of 26 patients having primary NNHL who were managed between January 1997 and December 2008, to evaluate and compare their clinical characteristics and treatment outcome.
Clinical variables, including age, sex, stage, and treatment modality, were assessed. Disease free survival and overall survival were measured.
Survival curves were constructed using the KaplanMeier method. The log-rank test was used to compare them.
Results: Median age of our patients was 52.7 years.
Nasal obstruction, nasal discharge and epistaxis were the frequent symptoms in NNHL patients. Histology of NNHL were mainly large B-cell and follicular lymphoma .Four patients (15.4%) were at stage I, 15 (57.6%) at stage II, and 7 (27%) were at stage III/IV.
The patients were treated with chemotherapy alone (27%) or chemotherapy plus radiotherapy (73%). At early stage (stage I/II) , the patients were managed with chemo-radiotherapy.
When the whole treatment was completed, 18 patients (69.2%) achieved complete response and remained disease free. After 25.9 months median follow-up, overall survival at 1 year was 87% and disease free survival at 1 year was 71%.
The difference in term of overall and disease free survival between stage I, II, III and IV was significant (Log rank test: p = 0.02 for overall survival and p = 0.01 for disease free survival).
Conclusion: From our study, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are particular and more studies have to be directed .
Author: Wafa AllamNabil IsmailiSanaa ElmajjaouiBel ElgueddariMohamed IsmailiHassan Errihani
Credits/Source: BMC Ear, Nose and Throat Disorders 2009, 9:11
Published on: 2009-11-17
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
